Author Affiliations

  1. DP Steensma,
  2. JS Caudill,
  3. A Pardanani,
  4. RF McClure,
  5. TL Lasho and
  6. A Tefferi
  1. Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA. Steensma.david@mayo.edu

Abstract

Discovery of a constitutively activating point mutation of the Janus kinase 2 (JAK2) receptor-associated tyrosine kinase in patients with polycythemia vera (PV) and other BCR/ABL-negative myeloproliferative disorders prompted many groups around the world to examine diverse subsets of patients with myeloid diseases for the prevalence of the JAK2 V617F mutation and its clinical and pathological associations.